프리마켓
로그인 회원가입
ELTX
ELTX
Elicio Therapeutics Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$3.00
+0.00 +0.00%
🌙 7월 28일 4:00 AM ET (한국 7/28 17:00)
$2.99
-0.01 ▼ -0.33%

엘리시오 테라퓨틱스(ELTX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$70M
스몰캡
P/E
-
배당수익률
없음
52주 위치
3%
저점 +13% · 고점 -81%
애널리스트
적극 매수
B-
Fundamental health
vs. 미분류 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 43%
밸류에이션
데이터 부족
재무 안정
Top 45%
Index RUTP/E -EPS (ttm) -2.34Insider Own 38.49%Shs Outstand 18.6MPerf Week -1.32%
Market Cap 0.07BForward P/E -EPS next Y -17.53%Insider Trans -Shs Float 14.4MPerf Month -20%
Enterprise Value 0.07BPEG -EPS next Q -0.54Inst Own 14.14%Short Float 12.99%Perf Quarter -74.34%
Income -0.04BP/S -EPS this Y 19.86%Inst Trans 9.33%Short Ratio 1.12Perf Half Y -62.96%
Sales 0.00BP/B -EPS next 5Y -1.53%ROA -158.11%Short Interest 1.88MPerf YTD -62.31%
Book/sh -0.08P/C 4.71EPS past 3/5Y 85.75% 37.53%ROE -1076.34%52W High -81.25% ($16.00)Perf Year -69.67%
Cash/sh 0.64P/FCF -Sales past 3/5Y -ROIC -338.8%52W Low 12.78% ($2.66)Perf 3Y -70.53%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 43.68%Gross Margin -Volatility(W/M) 5.88% 11.84%Perf 5Y -97.2%
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.61Perf 10Y -
Dividend Ex-Date -Quick Ratio 2.24EPS Q/Q 24.99%Profit Margin -RSI (14) 35.78Recom 1.4
Dividend Gr. 3/5Y -Current Ratio 2.24Sales Q/Q -SMA20 -10.4% ($3.35)Beta 1.31Target Price $19.1
Payout -Debt/Eq -Earnings 2026/5/11SMA50 -57.08% ($6.99)Rel Volume 0.15Prev Close $3
Employees 33LT Debt/Eq -EPS/Sales Surpr. -39.78% -SMA200 -66.6% ($8.98)Avg Volume(3M) 1.68MPrice $3
IPO 2021/2/5Option/Short Yes/YesTrades 1608Volume 254,933Change -
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-12M (YoY -5%)

📊 Elicio Therapeutics Inc (ELTX) Investment Analysis

What kind of company is Elicio Therapeutics Inc?

엘리시오 테라퓨틱스(ELTX)
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧬 Elucidio Therapeutics is a clinical-stage biotech company developing immuno-oncology therapeutics based on its proprietary Amphiphile platform. By targeting lymph nodes to amplify immune responses, the company is clinically evaluating its candidate drugs against hard-to-treat solid tumors, including KRAS mutation-positive pancreatic and colorectal cancers.

Learn more about Elicio Therapeutics Inc →
Market Cap
$0.1B
Approx. KRW 0.1 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4752
Employees33people
IPO2021/02/05
Current Price$3.00 ≈ 4,110원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 11일 (월) · 장 마감 후 EPS -39.8%
🔔 Earnings release 2026년 3월 12일 (목) · 장 마감 후 EPS -1.1%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-1076.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-158.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-338.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
2.24
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.24
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$19.10
현재가 대비 +536.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
-17.5%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
-1.5%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-24.9%
평균 서프라이즈
2026.05.11
하회
실적 $-0.65 · 예상 $-0.47 -39.8%
2026.03.12
하회
실적 $-0.49 · 예상 $-0.45 -10.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+19.9%
평균
My positionMid-range
Low range Average High range
미분류 초소형주 Median 29.4% · Bottom 44%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-17.5%
부진
My positionBottom 25%
Low range Average High range
미분류 초소형주 Median 40.2% · Bottom 11%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
-1.5%
양호
My positionMid-range
Low range Average High range
미분류 초소형주 Median -3.5% · Top 42%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+85.8%
우수
My positionTop 5%
Low range Average High range
미분류 초소형주 Median 25.4% · Top 4%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+37.5%
양호
My positionMid-range
Low range Average High range
미분류 초소형주 Median 14.6% · Top 26%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -166%p below the market
ELTX -97.2% · S&P 500 +68.4%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-165.6%p
Significantly behind the market
vs Health Care (XLV)
-121.7%p
Significantly behind the sector average
1-year basis
vs S&P 500
-85.7%p
Significantly behind the market
vs Health Care (XLV)
-89.4%p
Significantly behind the sector average
Rank among peers
5-year return Lower-Mid (lower 44%) Based on 245 peers
1-year return Lower-Mid (lower 32%) Based on 315 peers
Current position within 52-week range
Low (-12.8%p) High (-81.3%p)
Current price is 12.8% above the 52-week low and 81.3% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-81.5%
Annualized volatility
289.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $3.00 below the midline ($3.36). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD -1.034 · Signal -1.276 · Hist 0.242. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 36.0 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 16.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Valuation data is insufficient

Key metrics such as PER and PBR are unavailable, so valuation is omitted.

Who owns it?

Ownership is broadly stable
Institutional net buying +9.3% · Short interest elevated 13.0% · Short interest up +2.1pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+9.3%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 14.1%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 38.5%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 47.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
13.0%
Somewhat high
Healthcare 초소형주 Median 3.9%
Past 90 days 📈 +2.1%p increase
Short interest days to cover
1.1 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 18.6M주
Float (tradable shares) 14.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ELTX

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
ELTX ELTX This Stock
$70.4M- - -1076.34% - +0.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 엘리시오 테라퓨틱스(ELTX)?

엘리시오 테라퓨틱스(ELTX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ELTX?

The market cap of ELTX is approximately $70M, ranking 4,752 within its sector.

What is the 52-week high and low for ELTX?

ELTX has recorded a 52-week high of $16.00 and a low of $2.66.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.